2021 American Transplant Congress Archives - Page 2 of 139

ATC 2021 Virtual Connect is an all-new, completely enhanced virtual meeting experience. The ATC program is built in Eastern Time Zone.

Unclear Implications of Tacrolimus Time in Therapeutic Range as a Predictor of Acute Rejection in Renal Transplant Recipients Undergoing Early Corticosteroid Withdrawal

D. Pierce, P. West-Thielke, Z. Hajjiri, S. Gaitonde, I. Tzvetanov, E. Benedetti, A. Lichvar
Understanding Delays to Pediatric Kidney Transplant Wait-List Activation: Providers and Families Weigh in

C. M. Farkas-Skiles¹, A. Feinsinger², R. Pines³, A. D. Waterman⁴
Understanding Early Transplant Preparation: CKD 3-5 Patients’ Transplant Knowledge and Actions at Kaiser Permanente Southern California

R. Pines¹, S. H. Kawakita², G. H. Kim³, O. Ranasinghe⁴, B. Mittman⁵, B. Dub⁵, H. Wilhalme³, A. D. Waterman³
Understanding Transplant Decision Making Concerns for African, Caribbean and Black Canadian Patients with End-Stage Kidney Disease

N. Singh¹, A. Wasim¹, W. Hajjar¹, K. Mohan¹, N. El-Dassouki¹, H. Habbal¹, L. Angarso¹, A. Dychiao¹, S. Macanovic¹, A. D. Waterman², I. Mucsi¹
Unquantified Blips Lead to CMV Slips – Post Transplant CMV Monitoring in High Risk Kidney Transplant Recipients

A. T. Payne¹, J. G. Timpone², A. Gilbert², B. Thomas², B. K. Lindner²
Update on Domino Liver Transplants – A Registry Report

R. Gruessner, J. Renz, A. Gruessner
Update on Pancreas Retransplantation- A Registry Analysis

A. Gruessner, J. Renz, S. Saggi, R. Gruessner
Urinary Exosomal Cystatin C and Lipopolysaccharide Binding Protein as Biomarkers for Monitoring Antibody-mediated Rejection After Kidney Transplantation

M. Kim, S. Lim, S. Shin
Urinary Exosome Mrna Signature for the Diagnosis of Human Kidney Transplant Rejection

R. El Fekih¹, J. Hurley², V. Tadigotla², A. Alghamdi³, A. Srivastava⁴, C. Coticchia², J. Choi¹, H. Allos⁵, k. yatim⁵, J. Alhaddad⁵, S. Eskandari⁵, P. Chu⁵, A. Mihali⁵, I. Lape⁵, M. Lima Filho⁵, B. Ayoma⁵, A. Chandraker⁵, K. Safa⁶, J. Markmann⁶, L. Riella⁶, R. Formica⁷, J. Skog², J. Azzi⁵
Urine Donor-derived Cell-free is Valuable for Predicting BK Polyomavirus-associated Nephropathy in Kidney Transplant Recipients

G. Huang¹, X. Chen¹, Y. Huang¹, J. Li¹, R. Deng¹, W. Chen², J. Qiu¹, S. Deng¹, G. Chen¹, Q. Fu¹, C. Wu¹, J. Fei¹, L. Liu¹, L. Chen¹, C. Wang¹
Use of a Novel Bead-based Assay to Measure the Impact of Imlifidase on ABO IgG Antibodies

A. Halpin¹, B. Motyka², T. Ellis², J. Pearcey², T. L. Lowary³, A. Runström⁴, L. Winstedt⁴, R. Bockermann⁴, S. Järnum⁴, A. Robertson⁴, L. J. West⁵
Use of Donor Blood Expedites HCV Genotyping and Allows Earlier DAA Initiation for Recipients of HCV+ Kidneys

B. Lonze, N. Ali, R. Montgomery, Z. Stewart Lewis
Use of Donor-Derived Cell-Free DNA for Assessment of Allograft Rejection After Change in Maintenance Immunosuppression Regimens in the First Year Post Kidney Transplant

M. Walsh, V. Peev, L. Lineberger, M. Brokhof, N. Kenyon, N. Alvey
Use of Donor-Derived Cell-Free DNA in Children with Kidney Transplantation: A Pilot Study

E. Winnicki, J. Brennan, M. McEnhill, P. Brakeman, E. Ku
Use of Granulocyte Colony Stimulating Factor After Lung Transplantation is Not Associated with Increased Likelihood of Acute Cellular Rejection

S. Fredrick¹, C. Iasella², L. Sacha³, R. Rivosecchi³, M. Morrell³, P. Sanchez³, J. Pilewski³, M. Snyder³, J. McDyer³, C. Moore³
Use of Hepatitis B N.A.T. Positive Kidneys in Hepatitis B Immune Recipients

E. Stephenson¹, B. Nangunuri², T. McCune³
Use of Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients: A Scoping Review

A. G. Anderson, M. Eubank, K. Murray
Use of Microbial Cell Free DNA Sequencing in Solid Organ Transplant Patients

S. Chang, P. Gaynor, A. Multani, O. E. Beaird, M. Carlson, S. Yang, O. Garner, J. Schaenman
Utility of Donor-Derived Cell Free DNA for Detecting ABMR in Patients With AT1R Antibodies

S. Kant¹, D. Kumar², I. Moinuddin², T. Alhamad³, M. Haris³, J. Gray⁴, B. Dale⁴, M. Bettinotti¹, D. C. Brennan¹
Utility of Follow-up Biopsies After Acute Rejection in Pediatric Kidney Transplantation

S. S. Raza¹, V. Hauptfeld-Dolejsek¹, F. Rosenblum¹, E. C. Mroczek-Musulman², D. R. Kelly², M. Seifert¹
Utility of Non-Invasive Rejection Biomarkers to Guide Immunomodulation in Kidney Transplant Patients with Active Covid-19 Infection

J. Christensen, G. Gupta, A. Bryson, S. Paluri, R. Thompson, S. Sterling, N. Vissichelli, P. Kimball, D. Kumar
Utility of Screening-Bead Assay in Post-Transplant Testing of Donor-Specific Antibodies (DSA) and Antibody-mediated Rejection (ABMR) in Renal Allografts

A. Agrawal¹, E. Dijke², A. Murray³, P. Campbell³
Utilization of Donor-Derived Cell-Free DNA Testing in Kidney Transplantation: Do One Month Values Have Any Prognostic Significance?

R. J. Stratta, A. Farney, J. Rogers, G. Orlando, A. Reeves-Daniel, A. Mena-Gutierrez, N. Sakhovskaya, C. Jay
Utilization of Living Donor Liver Transplant for Patients Who Travel for Transplant in the United States

H. J. Braun, D. Amara, A. M. Shui, P. Stock, R. Hirose, F. Delmonico, N. L. Ascher
Utilization of Pre-Procurement Donor Liver Biopsy in Donation-after-circulatory-Death Liver Transplantation

A. C. Bolognese¹, N. Neidlinger¹, C. Sparks², A. Schneider², A. M. D'Alessandro¹, D. P. Foley¹
Utilizing Risk Factors to Guide Prevention of Invasive Fungal Infections in Liver Transplant Recipients

K. Fitton, A. Chan, C. Truax, B. Sirandas, T. Larson, L. Smith, A. Carlson